CILcare to present its advances on preclinical hearing loss models at IEB 2022

CILcare will present its latest advances on preclinical hearing loss models at IEB 2022

CILcare is glad to announce that its R&D team will be presenting its latest advances on preclinical hearing loss models at the 57th Inner Ear Biology workshop in Trieste, Italy, on September 10-13 2022.

CILcare’s R&D team is looking forward to joining the next IEB edition, the first one occurring since the beginning of the pandemic! Come and attend our 3 poster presentations on preclinical hearing loss models:

Development of Noise-Induced Hearing Loss Rat Models for Preclinical Efficacy Assessment

Exposure to intense or prolonged sounds has a damaging effect on cochlear structures which can be irreversible. Acoustic trauma can lead to permanent or transitory threshold shifts, with different pathological features, including hair cell loss, degeneration of the auditory nerve, and damage to ribbon synapses. Carolanne Coyat, PhD, R&D Project Manager, will be presenting rat models developed by CILcare to mimic different aspects of noise-induced hearing loss and to test the efficacy of drugs targeting synaptogenesis, cell death, oxidative stress, inflammatory responses, or cell regeneration. This poster describes a valuable tool that gives insight into future pharmacological treatments.

Development of a Cisplatin-Induced Hearing Loss Rat Model for Preclinical Efficacy Assessment

Cisplatin is a platinum-based chemotherapeutic widely used in the treatment of many cancers, which is associated with serious side effects, such as progressive and irreversible hearing loss. CILcare has developed a robust and translational rat model to understand the mechanisms of cisplatin’s ototoxicity and to develop effective treatments by testing the protective effects of drugs against cisplatin’s ototoxicity in comparison to sodium thiosulfate. This poster will be presented by Marion Souchal, PhD, R&D Project Manager.

Ototoxic Effects of Drugs Used in Covid-19 in Comparison to Well-Known Ototoxic Agent Cisplatin in Male CBA JRJ Mice

Many different medications are being investigated to treat Covid-19, some of which have been identified as potentially ototoxic. Sylvie Pucheu, PhD, Co-Founder & Chief Scientific Officer, will be giving a presentation on the ototoxic side effects of Hydroxychloroquine, Azithromycine, and Colchicine, administered similarly to clinic protocol (route of administration, doses, and regimen schedule). Cisplatin was used for comparative purposes as a reference compound as it is well-known for having ototoxic side-effects.

The Inner Ear Biology Workshop is an annual event dedicated to hearing loss and its genetic bases. This year it will focus on the genetics, pathology and therapies of the inner ear, highlighting the importance to bridge basic research into clinical application.

Hearing loss is a major global health issue affecting around 1.5 billion people worldwide, with an increasing prevalence, estimated to reach 2.5 billion people in 2050. Aging, noise exposure and auditory side-effects of multiple drugs constitute some major causes of hearing loss. So far, there are no approved drugs on the market for hearing loss and tinnitus, thus resulting in an important unmet medical need.

Learn more about the Inner Ear Biology Forum here.

Learn more about CILcare’s events here.

Share the Post: